---
layout: default
title: Ribavirin
description: "Ribavirin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚ä¸­ç­‰è­‰æ“šç­‰ç´š L3ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 147
evidence_level: L1
indication_count: 10
---

# Ribavirin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L3</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ribavirinï¼šå¾ C å‹è‚ç‚åˆ°æ…¢æ€§ B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ribavirin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Ribavirin æ˜¯ä¸€ç¨®æŠ—ç—…æ¯’è—¥ç‰©ï¼ŒåŸæœ¬èˆ‡å¹²æ“¾ç´ æˆ–å…¶ä»–æŠ—ç—…æ¯’è—¥ç‰©ä½µç”¨æ²»ç™‚æ…¢æ€§ C å‹è‚ç‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**æ…¢æ€§ B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“ (Chronic Hepatitis B Virus Infection)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **30+ å€‹è‡¨åºŠè©¦é©—**æ”¯æŒé€™å€‹ç ”ç©¶æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æ…¢æ€§ C å‹è‚ç‚ï¼ˆèˆ‡ peginterferon æˆ– DAA ä½µç”¨ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | chronic hepatitis B virus infectionã€hepatopulmonary syndromeã€early-onset familial noncirrhotic portal hypertensionã€idiopathic copper-associated cirrhosisã€hepatoportal sclerosisã€primitive portal vein thrombosisã€chronic hepatitis C virus infectionã€hepatic porphyriaã€IgG4-related pachymeningitisã€IgG4-related mesenteritis |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.86% |
| è­‰æ“šç­‰ç´š | L3 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. chronic hepatitis B virus infection</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.86%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p>Ribavirin æ˜¯ä¸€ç¨®æ ¸è‹·é¡ä¼¼ç‰©ï¼Œå…·æœ‰å»£è­œæŠ—ç—…æ¯’æ´»æ€§ã€‚å®ƒçš„ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š</p>
<ul>
<li>æŠ‘åˆ¶ç—…æ¯’ RNA èšåˆé…¶</li>
<li>èª˜å°ç—…æ¯’åŸºå› çµ„çªè®Š</li>
<li>èª¿ç¯€å®¿ä¸»å…ç–«åæ‡‰</li>

</ul>
<p>é›–ç„¶ ribavirin ä¸»è¦è¢«æ‰¹å‡†ç”¨æ–¼ C å‹è‚ç‚çš„æ²»ç™‚ï¼Œä½†å…¶å»£è­œæŠ—ç—…æ¯’æ´»æ€§ä½¿å…¶å°å…¶ä»–ç—…æ¯’ï¼ˆåŒ…æ‹¬ B å‹è‚ç‚ç—…æ¯’ï¼‰å¯èƒ½å…·æœ‰æ½›åœ¨ç™‚æ•ˆã€‚åœ¨æŸäº›æƒ…æ³ä¸‹ï¼Œç‰¹åˆ¥æ˜¯ B/C å‹è‚ç‚åˆä½µæ„ŸæŸ“æˆ– D å‹è‚ç‚ï¼ˆéœ€è¦ B å‹è‚ç‚ç—…æ¯’ä½œç‚ºè¼”åŠ©ç—…æ¯’ï¼‰çš„æ‚£è€…ä¸­ï¼Œribavirin èˆ‡å¹²æ“¾ç´ çš„çµ„åˆå·²è¢«ç ”ç©¶ã€‚</p>

<p>ç„¶è€Œï¼Œéœ€è¦æ³¨æ„çš„æ˜¯ï¼Œç›®å‰ B å‹è‚ç‚çš„æ¨™æº–æ²»ç™‚æ˜¯æ ¸è‹·é¡ä¼¼ç‰©ï¼ˆå¦‚ entecavirã€tenofovirï¼‰æˆ–å¹²æ“¾ç´ ï¼Œribavirin ä¸¦ä¸æ˜¯æ¨™æº–æ–¹æ¡ˆçš„ä¸€éƒ¨åˆ†ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00117533">NCT00117533</a></td>
<td>Phase 4</td>
<td>æœªçŸ¥</td>
<td>20</td>
<td>Peginterferon alfa-2b + ribavirin æ²»ç™‚ B/D å‹è‚ç‚åˆä½µæ„ŸæŸ“</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01318694">NCT01318694</a></td>
<td>Phase 3</td>
<td>å·²å®Œæˆ</td>
<td>1081</td>
<td>Alisporivir + peginterferon + ribavirin æ²»ç™‚ C å‹è‚ç‚</td>
</tr>
</tbody>
</table>

<p>ï¼ˆæ³¨ï¼šå¤§å¤šæ•¸è‡¨åºŠè©¦é©—é‡å° C å‹è‚ç‚ï¼Œéƒ¨åˆ†æ¶‰åŠ B/C å‹åˆä½µæ„ŸæŸ“ï¼‰</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<p>ç›®å‰ä¸»è¦æ–‡ç»é›†ä¸­åœ¨ C å‹è‚ç‚æ²»ç™‚ï¼Œé‡å°å–®ç´” B å‹è‚ç‚ç—…æ¯’æ„ŸæŸ“çš„ç ”ç©¶æœ‰é™ã€‚</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hepatopulmonary syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25161156/" target="_blank">25161156</a></td><td>2014</td><td>Article</td><td>International journa</td><td>Occult interferon Î±-induced pulmonary granulomatosis despite...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. early-onset familial noncirrhotic portal hypertension</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. idiopathic copper-associated cirrhosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. hepatoportal sclerosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. primitive portal vein thrombosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.57%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. hepatic porphyria</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.50%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ16 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9305294/" target="_blank">9305294</a></td><td>1997</td><td>Article</td><td>Southern medical jou</td><td>Chronic hepatitis C.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15233692/" target="_blank">15233692</a></td><td>2004</td><td>Article</td><td>Alimentary pharmacol</td><td>Hepatitis C virus-related extra-hepatic disease--aetiopathog...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11685805/" target="_blank">11685805</a></td><td>2001</td><td>Article</td><td>Clinics in liver dis</td><td>Extrahepatic manifestations of infection with hepatitis C vi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/10468647/" target="_blank">10468647</a></td><td>1999</td><td>Article</td><td>Alternative medicine</td><td>Hepatitis C: epidemiology and review of complementary/altern...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28641714/" target="_blank">28641714</a></td><td>2017</td><td>Article</td><td>The American journal</td><td>Hepatitis C Treatment in Patients With Porphyria Cutanea Tar...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 11 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. IgG4-related pachymeningitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.44%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. IgG4-related mesenteritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. IgG4-related aortitis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.31%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | é€Ÿå¨å¹²è»Ÿè† å›Š100æ¯«å…‹ç­‰ | è† å›Š/éŒ åŠ‘ | èˆ‡å¹²æ“¾ç´ æˆ– DAA ä½µç”¨æ²»ç™‚æ…¢æ€§ C å‹è‚ç‚ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- æº¶è¡€æ€§è²§è¡€ï¼šæœ€å¸¸è¦‹çš„åš´é‡ä¸è‰¯åæ‡‰
- è‡´ç•¸æ€§ï¼šå­•å©¦ç¦ç”¨ï¼Œæ²»ç™‚æœŸé–“åŠæ²»ç™‚å¾Œ 6 å€‹æœˆéœ€é¿å­•
- å¿ƒè‡Ÿæ¯’æ€§ï¼šå¯èƒ½åŠ é‡å¿ƒè‡Ÿç–¾ç—…

**ç¦å¿Œç—‡ï¼š**
- å¦Šå¨ æˆ–å¯èƒ½æ‡·å­•çš„å©¦å¥³
- åš´é‡å¿ƒè‡Ÿç–¾ç—…
- è¡€ç´…ç´ ç•°å¸¸
- è‡ªé«”å…ç–«æ€§è‚ç‚




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**high-fat foods** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©å¸æ”¶ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šè«‹è«®è©¢é†«å¸«æˆ–è—¥å¸«äº†è§£è©³ç´°å»ºè­°ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰å¯èƒ½å½±éŸ¿æŠ—ç—…æ¯’è—¥ç‰©ä»£è¬
- å»ºè­°ï¼šé¿å…ä½µç”¨


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Anemia** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šè²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Lung Diseases** ğŸŸ¢ Minor
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚

**è…è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
é›–ç„¶ ribavirin å…·æœ‰å»£è­œæŠ—ç—…æ¯’æ´»æ€§ï¼Œä¸”æœ‰ä¸€äº›ç ”ç©¶æ¢è¨å…¶åœ¨ B/D å‹è‚ç‚åˆä½µæ„ŸæŸ“ä¸­çš„æ‡‰ç”¨ï¼Œä½†ç›®å‰ç¼ºä¹å……åˆ†è­‰æ“šæ”¯æŒå–®ç¨ç”¨æ–¼æ…¢æ€§ B å‹è‚ç‚çš„æ²»ç™‚ã€‚ç¾æœ‰çš„ B å‹è‚ç‚æ¨™æº–æ²»ç™‚ï¼ˆentecavirã€tenofovirï¼‰å·²è­‰æ˜æœ‰æ•ˆä¸”å®‰å…¨ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é€²è¡Œå°ç…§è©¦é©—æ¯”è¼ƒ ribavirin èˆ‡ç¾æœ‰ B å‹è‚ç‚æ²»ç™‚çš„ç™‚æ•ˆ
- æ˜ç¢º ribavirin åœ¨ B å‹è‚ç‚æ²»ç™‚ä¸­çš„å®šä½ï¼ˆè¼”åŠ©æ²»ç™‚ï¼Ÿç‰¹å®šäºç¾¤ï¼Ÿï¼‰
- è©•ä¼°èˆ‡ç¾æœ‰æ ¸è‹·é¡ä¼¼ç‰©ä½µç”¨çš„å®‰å…¨æ€§å’Œç™‚æ•ˆ
- ç‰¹åˆ¥æ³¨æ„æº¶è¡€æ€§è²§è¡€ç­‰åš´é‡ä¸è‰¯åæ‡‰çš„ç›£æ¸¬

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Alfacalcidol]({{ "/drugs/alfacalcidol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Dupilumab]({{ "/drugs/dupilumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Acitretin]({{ "/drugs/acitretin/" | relative_url }}) - è­‰æ“šç­‰ç´š L3
- [Inositol]({{ "/drugs/inositol/" | relative_url }}) - è­‰æ“šç­‰ç´š L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ribavirinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ribavirin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ribavirin,
  title = {Ribavirinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ribavirin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
